<!DOCTYPE html>
<html lang="en">
<head>
<?php $id='1694-1449'; include '../../seo.php';?>
<?php include '../../side-nav.php';?>
<div class="page-content">
<!--section-->
<div class="section mt-0">
<div class="breadcrumbs-wrap">
<div class="container">
<div class="breadcrumbs">
<a href="https://sprintdiagnostics.in/">Home</a>
<a href="https://www.sprintdiagnostics.in/hyderabad/profile/">Profile</a>
<span>IHC - diagnostic panel </span>
</div>
</div>
</div>
</div>
<!--//section-->
<!--section-->
<div class="section page-content-first">
<div class="container mt-6">
<div class="row">
<div class="col-md-8 col-lg-8 mt-0 mt-md-0 mb-4">
<h1 class="test-h1">IHC - diagnostic panel; Metastases from unknown primary-customised panels of antibodies from the list based on morphology of the tumour </h1>
<div class="post-text">
<p>Immunohistochemistry (IHC) has played an essential role in the categorization and identification of different tumor types in clinical oncology. When a patient presents with metastatic cancer, but the primary site remains elusive despite a thorough examination, these cases are referred to as cancers of unknown primary (CUP). To tackle this diagnostic challenge, an IHC diagnostic panel, customized from a list of antibodies based on the morphology of the tumor, can be employed. This panel utilizes five markers tailored to the patient's individual case, helping identify the primary tumor type, which is vital for appropriate treatment planning.</p>

<p>An essential premise of the IHC diagnostic panel is its adaptability, the capacity to choose the most relevant markers based on the tumor's histological and morphological features. The chosen markers target specific proteins that are frequently expressed in certain types of cancer. The expression of these markers, or lack thereof, provides valuable insights into the possible origin of the metastatic cells. By interpreting these patterns, the pathologist can suggest a probable primary site, leading to a more targeted approach in managing the patient's condition.</p>

<p>However, it is crucial to note that no IHC panel, no matter how comprehensive, can replace the importance of a thorough clinical evaluation, radiological investigations, and a detailed pathology review. The IHC panel for CUP should be viewed as an adjunct tool that helps in the diagnostic process, particularly in challenging cases where conventional methods have not provided sufficient information.</p>
<div class="table-wrap">
<table class="table table-striped">
	<thead>
		<tr>
			<th scope="col">Profile Name</th>
			<td scope="col">IHC - diagnostic panel; Metastases from unknown primary-customised panels of antibodies from the list based on morphology of the tumour </td>
		</tr>
	</thead>
	<tbody>
		<tr>
			<th scope="row">Sample Type</th>
			<td>Tissue</td>
		</tr>
		<tr>
			<th scope="row">Preparations Required</th>
			<td>None</td>
		</tr>
		<tr>
			<th scope="row">Report Time</th>
			<td>5 Days</td>
		</tr>
		<tr>
			<th scope="row">Price in Hyderabad</th>
			<td>â‚¹ 7500 </td>
		</tr>
	</tbody>
</table>
</div>
<div class="post-text">
	<h2 class="test-h2 mt-3"> </h2>
	<p> </p>
	<h2 class="test-h2 mt-3"> </h2>
	<p> </p>
	<!--section achieved-->
	<?php include "../../include/iconsbox.php" ?>
	<!--//section achieved-->
	<h2 class="test-h2 mt-3">What is the purpose of the IHC Diagnostic Panel for CUP?</h2>
<p>The IHC Diagnostic Panel for CUP is intended to help identify the primary tumor in patients with metastatic cancer
    when the primary site is unknown.</p>
<h2 class="test-h2 mt-3">Do I need to fast before this test?</h2>
<p>No, this test is performed on a tissue sample, so there is no need to fast.</p>
<h2 class="test-h2 mt-3">What are these markers?</h2>
<p>These markers are specific proteins typically expressed in certain types of cancer. The expression of these proteins
    in the tumor tissue can provide clues about the origin of the metastatic cells.</p>
<h2 class="test-h2 mt-3">How is the sample for the test obtained?</h2>
<p>The sample for the test is usually obtained through a biopsy procedure, where a small piece of the tumor tissue is
    removed for testing.</p>
<h2 class="test-h2 mt-3">What does it mean if a marker is positive?</h2>
<p>A positive marker means that the tested protein is present in the tissue sample. Depending on the specific marker,
    this could suggest a likely primary tumor site.</p>
<h2 class="test-h2 mt-3">What does it mean if a marker is negative?</h2>
<p>A negative marker means that the tested protein is not present in the tissue sample. This result can help rule out
    certain primary sites.</p>
<h2 class="test-h2 mt-3">How long does it take to get the results of the test?</h2>
<p>The turnaround time for the test results can vary, but generally, you can expect results within 7 to 10 days.</p>
<h2 class="test-h2 mt-3">What factors can affect the test results?</h2>
<p>The test results can be affected by technical issues such as the quality of the tissue sample, or biological factors
    such as the presence of necrosis (cell death) in the tissue.</p>
<h2 class="test-h2 mt-3">What happens if the primary site still cannot be identified after the test?</h2>
<p>If the primary site cannot be identified even after the test, the patient will be managed based on the identified
    metastatic disease. Further tests may be done, and the most effective treatment plan will be chosen based on the
    patient's overall health condition and the nature of the metastatic tumors.</p>
<h2 class="test-h2 mt-3">Is there any special preparation needed before the test?</h2>
<p>No special preparation is needed before the test. However, be sure to follow any instructions given by your doctor
    regarding the biopsy procedure.</p>
<h2 class="test-h2 mt-3">What precautions need to be taken before and after the test?</h2>
<p>Before the test, inform your doctor about any medications you are taking, as some drugs can interfere with the
    procedure. After the test, follow your doctor's instructions for care and any follow-up appointments.</p>
<h2 class="test-h2 mt-3">Are there any risks associated with the biopsy procedure?</h2>
<p>As with any procedure that involves penetrating the skin, there is a small risk of infection or bleeding. There may
    also be other risks depending on the specific location of the biopsy.</p>
<h2 class="test-h2 mt-3">Who should I consult if the test results are abnormal?</h2>
<p>If the test results are abnormal, you should consult with an oncologist, a doctor who specializes in cancer
    treatment. The oncologist will interpret the results in the context of your overall health condition and symptoms to
    recommend the best course of action.</p>
<h2 class="test-h2 mt-3">How often should this test be done?</h2>
<p>The test is typically done once to aid in the diagnosis of CUP. However, in some cases, it may be repeated if more
    tissue samples are needed or if you have a recurrence of cancer.</p>
<h2 class="test-h2 mt-3">How reliable is the IHC panel for CUP?</h2>
<p>While the IHC panel for CUP can provide valuable clues about the primary tumor, it is not always definitive. It
    should be used in conjunction with other diagnostic methods, including clinical evaluation and radiological
    investigations.</p>
<h2 class="test-h2 mt-3">What is the utility of this IHC panel in the treatment plan?</h2>
<p>The results of the IHC panel can significantly influence the treatment strategy. Identification of the primary site can allow for a more targeted treatment approach, potentially improving outcomes and reducing unnecessary side effects associated with broad-spectrum therapies.</p> 
<h2 class="test-h2 mt-3">Can this test differentiate between different types of cancer?</h2>
<p>Yes, the IHC panel can often differentiate between various types of cancer based on the expression of specific markers. However, the interpretation of results should always be done in the context of other clinical and diagnostic information.</p>
<h2 class="test-h2 mt-3">Are there limitations to the IHC panel for CUP?</h2>
<p>Yes, there are limitations. For instance, the panel cannot always definitively identify the primary site. Also, some cancers do not express the typical markers or may express markers usually associated with other types of tumors, which can make the results challenging to interpret.</p>
<h2 class="test-h2 mt-3">Does a positive result for a specific marker guarantee that the primary site has been accurately identified?</h2>
<p>No, a positive result for a specific marker does not guarantee an accurate identification of the primary site. It simply suggests a possible origin. This test is a part of the diagnostic process, and results should be interpreted alongside other clinical and diagnostic data.</p>
<h2 class="test-h2 mt-3">Can this test be used for monitoring disease progression or response to treatment?</h2>
<p>No, this IHC panel is not typically used for monitoring disease progression or response to treatment. It is primarily a diagnostic tool used to identify the potential primary site of the tumor.</p>
<p>The IHC panel for CUP, while not definitive, offers valuable insights to support the diagnostic process. It highlights the importance of precision in oncology and the movement towards personalized medicine - where treatment is tailored to the individual patient based on their specific disease characteristics. Remember, each patient is unique, and so is their cancer. Understanding this can lead to more effective treatment strategies, fostering hope in the challenging journey of cancer treatment and recovery.</p>



</div>		
</div>			
</div>
<!--form section-->
<?php include "../../include/bookslot.php" ?>
<!--form section-->
</div>
</div>
<!--//section-->
</div>
</div>
<?php include '../../footer.php';?>
</body>
</html>